1-20 of 23
flt3 gene
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Effect of DNMT3A variant allele frequency and double mutation on clinicopathologic features of patients with de novo AML

Damodaran Narayanan, Olga Pozdnyakova, Robert P. Hasserjian, Sanjay S. Patel, Olga K. Weinberg
Journal: Blood Advances
Blood Adv (2021) 5 (11): 2539–2549.
https://doi.org/10.1182/bloodadvances.2021004250
Published: 2021
Includes: Supplemental data
Journal Articles

SETBP1 overexpression acts in the place of class-defining mutations to drive FLT3 -ITD–mutant AML

Suruchi Pacharne, Oliver M. Dovey, Jonathan L. Cooper, Muxin Gu, Mathias J. Friedrich, Sandeep S. Rajan, Maxim Barenboim, Grace Collord, M. S. Vijayabaskar, Hannes Ponstingl, Etienne De Braekeleer, Ruben Bautista, Milena Mazan, Roland Rad, Konstantinos Tzelepis, Penny Wright, Malgorzata Gozdecka, George S. Vassiliou
Journal: Blood Advances
Blood Adv (2021) 5 (9): 2412–2425.
https://doi.org/10.1182/bloodadvances.2020003443
Published: 2021
Includes: Supplemental data
Journal Articles

13q12.2 deletions and FLT3 overexpression in acute leukemias

Caroline Pires Poubel, Mariana Boroni, Mariana Emerenciano
Journal: Blood Advances
Blood Adv (2021) 5 (8): 2075–2078.
https://doi.org/10.1182/bloodadvances.2020003643
Published: 2021
Journal Articles

Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia

Clinical Trials & Observations
Christopher J. Walker, Krzysztof Mrózek, Hatice Gulcin Ozer, Deedra Nicolet, Jessica Kohlschmidt, Dimitrios Papaioannou, Luke K. Genutis, Marius Bill, Bayard L. Powell, Geoffrey L. Uy, Jonathan E. Kolitz, Andrew J. Carroll, Richard M. Stone, Ramiro Garzon, John C. Byrd, Ann-Kathrin Eisfeld, Albert de la Chapelle, Clara D. Bloomfield
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1474–1482.
https://doi.org/10.1182/bloodadvances.2020003727
Published: 2021
Includes: Supplemental data
Journal Articles

Single-cell DNA sequencing reveals complex mechanisms of resistance to quizartinib

Clinical Trials & Observations
Cheryl A. C. Peretz, Lisa H. F. McGary, Tanya Kumar, Hunter Jackson, Jose Jacob, Robert Durruthy-Durruthy, Mark J. Levis, Alexander Perl, Benjamin J. Huang, Catherine C. Smith
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1437–1441.
https://doi.org/10.1182/bloodadvances.2020003398
Published: 2021
Includes: Supplemental data
Journal Articles

Quizartinib-resistant FLT3 -ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736

Andrew S. Moore, Amir Faisal, Grace W. Y. Mak, Farideh Miraki-Moud, Vassilios Bavetsias, Melanie Valenti, Gary Box, Albert Hallsworth, Alexis de Haven Brandon, Cristina P. R. Xavier, Randal Stronge, Andrew D. J. Pearson, Julian Blagg, Florence I. Raynaud, Rajesh Chopra, Suzanne A. Eccles, David C. Taussig, Spiros Linardopoulos
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1478–1491.
https://doi.org/10.1182/bloodadvances.2019000986
Published: 2020
Includes: Supplemental data
Journal Articles

Gilteritinib: potent targeting of FLT3 mutations in AML

Clinical Trials & Observations
Mark Levis, Alexander E. Perl
Journal: Blood Advances
Blood Adv (2020) 4 (6): 1178–1191.
https://doi.org/10.1182/bloodadvances.2019000174
Published: 2020
Journal Articles

The prognostic impact of FLT3 -ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting

Clinical Trials & Observations
Gunnar Juliusson, Martin Jädersten, Stefan Deneberg, Sören Lehmann, Lars Möllgård, Lovisa Wennström, Petar Antunovic, Jörg Cammenga, Fryderyk Lorenz, Emma Ölander, Vladimir Lj Lazarevic, Martin Höglund
Journal: Blood Advances
Blood Adv (2020) 4 (6): 1094–1101.
https://doi.org/10.1182/bloodadvances.2019001335
Published: 2020
Includes: Supplemental data
Journal Articles

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations

Clinical Trials & Observations
Theodore C. Tarver, Jason E. Hill, Leena Rahmat, Alexander E. Perl, Erkut Bahceci, Kenichi Mori, Catherine C. Smith
Journal: Blood Advances
Blood Adv (2020) 4 (3): 514–524.
https://doi.org/10.1182/bloodadvances.2019000919
Published: 2020
Includes: Supplemental data
Journal Articles

Retinoic acid synergizes with the unfolded protein response and oxidative stress to induce cell death in FLT3-ITD + AML

Silvia Masciarelli, Ernestina Capuano, Tiziana Ottone, Mariadomenica Divona, Serena Lavorgna, Francesca Liccardo, Martyna Śniegocka, Serena Travaglini, Nelida I. Noguera, Alessandra Picardi, Vincenzo Petrozza, Alessandro Fatica, Luca Tamagnone, Maria Teresa Voso, Francesco Lo Coco, Francesco Fazi
Journal: Blood Advances
Blood Adv (2019) 3 (24): 4155–4160.
https://doi.org/10.1182/bloodadvances.2019000540
Published: 2019
Includes: Supplemental data
Journal Articles

LAM-003, a new drug for treatment of tyrosine kinase inhibitor–resistant FLT3-ITD–positive AML

Neil Beeharry, Sean Landrette, Sophia Gayle, Marylens Hernandez, Jeff E. Grotzke, Peter R. Young, Paul Beckett, Xuan Zhang, Bing Z. Carter, Michael Andreeff, Stephanie Halene, Tian Xu, Jonathan Rothberg, Henri Lichenstein
Journal: Blood Advances
Blood Adv (2019) 3 (22): 3661–3673.
https://doi.org/10.1182/bloodadvances.2019001068
Published: 2019
Includes: Supplemental data
Journal Articles

Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome

Emily F. Mason, Robert P. Hasserjian, Nidhi Aggarwal, Adam C. Seegmiller, Olga Pozdnyakova
Journal: Blood Advances
Blood Adv (2019) 3 (21): 3322–3332.
https://doi.org/10.1182/bloodadvances.2019000328
Published: 2019
Includes: Supplemental data
Journal Articles

Gilteritinib induces differentiation in relapsed and refractory FLT3 -mutated acute myeloid leukemia

Clinical Trials & Observations
Christine M. McMahon, Jonathan Canaani, Bryan Rea, Rachel L. Sargent, Julianne N. Qualtieri, Christopher D. Watt, Jennifer J. D. Morrissette, Martin Carroll, Alexander E. Perl
Journal: Blood Advances
Blood Adv (2019) 3 (10): 1581–1585.
https://doi.org/10.1182/bloodadvances.2018029496
Published: 2019
Includes: Supplemental data
Journal Articles

Clinicopathologic and genetic characterization of nonacute NPM1 -mutated myeloid neoplasms

Clinical Trials & Observations
Sanjay S. Patel, Caleb Ho, Ryan N. Ptashkin, Sam Sadigh, Adam Bagg, Julia T. Geyer, Mina L. Xu, Thomas Prebet, Emily F. Mason, Adam C. Seegmiller, Elizabeth A. Morgan, David P. Steensma, Eric S. Winer, Waihay J. Wong, Robert P. Hasserjian, Olga K. Weinberg
Journal: Blood Advances
Blood Adv (2019) 3 (9): 1540–1545.
https://doi.org/10.1182/bloodadvances.2019000090
Published: 2019
Journal Articles

Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia

Pamela J. Sung, Mayumi Sugita, Holly Koblish, Alexander E. Perl, Martin Carroll
Journal: Blood Advances
Blood Adv (2019) 3 (7): 1061–1072.
https://doi.org/10.1182/bloodadvances.2018029850
Published: 2019
Includes: Supplemental data
Journal Articles

Role of CYP3A4 in bone marrow microenvironment–mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors

Yu-Ting Chang, Daniela Hernandez, Salvador Alonso, Minling Gao, Meng Su, Gabriel Ghiaur, Mark J. Levis, Richard J. Jones
Journal: Blood Advances
Blood Adv (2019) 3 (6): 908–916.
https://doi.org/10.1182/bloodadvances.2018022921
Published: 2019
Includes: Supplemental data
Journal Articles

NPM1 mutated AML can relapse with wild-type NPM1 : persistent clonal hematopoiesis can drive relapse

Clinical Trials & Observations
Alexander Höllein, Manja Meggendorfer, Frank Dicker, Sabine Jeromin, Niroshan Nadarajah, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach
Journal: Blood Advances
Blood Adv (2018) 2 (22): 3118–3125.
https://doi.org/10.1182/bloodadvances.2018023432
Published: 2018
Journal Articles

When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter

Gregory W. Roloff, Elizabeth A. Griffiths
Journal: Blood Advances
Blood Adv (2018) 2 (21): 3070–3080.
https://doi.org/10.1182/bloodadvances.2018020206
Published: 2018
Journal Articles

Prognostic impact of low allelic ratio FLT3- ITD and NPM1 mutation in acute myeloid leukemia

Clinical Trials & Observations
Masahiro Sakaguchi, Hiroki Yamaguchi, Yuho Najima, Kensuke Usuki, Toshimitsu Ueki, Iekuni Oh, Sinichiro Mori, Eri Kawata, Nobuhiko Uoshima, Yutaka Kobayashi, Shinichi Kako, Kenji Tajika, Seiji Gomi, Katsuhiro Shono, Kensuke Kayamori, Masao Hagihara, Junya Kanda, Hitoji Uchiyama, Junya Kuroda, Naoyuki Uchida, Yasushi Kubota, Shinya Kimura, Saiko Kurosawa, Nana Nakajima, Atsushi Marumo, Ikuko Omori, Yusuke Fujiwara, Shunsuke Yui, Satoshi Wakita, Kunihito Arai, Tomoaki Kitano, Kazuhiko Kakihana, Yoshinobu Kanda, Kazuteru Ohashi, Takahiro Fukuda, Koiti Inokuchi
Journal: Blood Advances
Blood Adv (2018) 2 (20): 2744–2754.
https://doi.org/10.1182/bloodadvances.2018020305
Published: 2018
Includes: Supplemental data
Journal Articles

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3 -ITD mutations

Clinical Trials & Observations
Mark J. Levis, Alexander E. Perl, Jessica K. Altman, Christopher D. Gocke, Erkut Bahceci, Jason Hill, Chaofeng Liu, Zhiyi Xie, Andrew R. Carson, Valerie McClain, Timothy T. Stenzel, Jeffrey E. Miller
Journal: Blood Advances
Blood Adv (2018) 2 (8): 825–831.
https://doi.org/10.1182/bloodadvances.2018015925
Published: 2018
Includes: Supplemental data